Updated:
Inscripta
Inscripta was established as a family office in Pleasanton, California, but the founding principal and wealth origin are not publicly disclosed.
Inscripta
Inscripta was established as a family office in Pleasanton, California, but the founding principal and wealth origin are not publicly disclosed. The firm's website redirects all pages to manus.bio, signaling a complete pivot from its earlier identity. The family office's strategy centers on synthetic biology and sustainable chemistry. Inscripta developed MAD7, a CRISPR-based gene-editing enzyme, which it licenses through madzymes.com. The now-defunct firm Inscripta focused on precision genome engineering; the office's capital now backs Manus, which produces bioalternatives to ingredients traditionally sourced via petrochemical or agricultural extraction. The office appears to invest in direct company-building and licensing revenue, though no named portfolio companies or co-investors are public. No team size, additional offices, or philanthropic vehicles are publicly listed. The most recent operational event is the rebranding to Manus, which occurred around the time the website redirected (per firm website, 2024). The office employs no publicly named professionals, and its AUM is undisclosed. The key structural differentiator is that Inscripta operates as an operating-company family office: rather than a passive investment vehicle, it built and spun out a biomanufacturing firm (Manus) and a gene-editing licensing arm (Madzymes), making it a hybrid of a family office and a venture builder.
General information
Firm type
Single Family Office
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Pleasanton
Corporate office
Pleasanton, CA, United States
Sector focus
Frequently asked questions
What is the relationship between Inscripta and Manus?
Inscripta, the family office, developed the technology and operations that now form Manus, a biomanufacturing company focused on replacing petrochemical-derived ingredients with bioalternatives. The firm's website now redirects to manus.bio, indicating that Manus is the primary operating entity (per firm website, 2024).
Does Inscripta still license the MAD7 gene-editing platform?
Yes. The MAD7 CRISPR-based enzyme is available through a separate program at madzymes.com. The family office continues to license the technology to third parties separately from the Manus biomanufacturing business (per firm website, 2024).
How does Inscripta's family office structure differ from a traditional single-family office?
Inscripta operates as an operating-company family office, meaning it builds and spins out technology ventures rather than simply managing a portfolio. It has created a gene-editing licensing platform (Madzymes) and a biomanufacturing firm (Manus), positioning itself as a venture builder alongside its investment function.
What investment sectors does Inscripta focus on?
The family office concentrates on synthetic biology and sustainable chemicals. Its core activity is producing bioalternatives to ingredients and materials traditionally sourced through petrochemical extraction, agriculture, or animal husbandry (per Manus website, 2024).
Is Inscripta a single-family office or multi-family office?
Inscripta appears to be structured as a single-family office, though the underlying family or wealth origin is not publicly disclosed. No evidence suggests it manages capital for multiple families.
Does Inscripta make direct investments in external companies?
There is no public evidence of direct investments in unrelated portfolio companies. Instead, Inscripta appears to deploy capital internally into its own ventures — Manus and Madzymes — rather than taking stakes in third-party firms.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: